Ombrabulin hydrochloride is primarily investigated for its potential in cancer therapy, particularly as a vascular disrupting agent. It targets and damages the blood vessels that supply tumors, leading to tumor cell death due to lack of oxygen and nutrients. This mechanism makes it a promising candidate for treating solid tumors, often in combination with other chemotherapy agents to enhance efficacy. Clinical studies have explored its use in various cancers, including soft tissue sarcomas and ovarian cancer, aiming to improve patient outcomes by inhibiting tumor growth and metastasis. Its application is still under research, with ongoing trials to determine optimal dosing and therapeutic combinations.